Loading...
•
Jun 30, 2021
Ultragenyx Q2 2021 Earnings Report
Ultragenyx reported Q2 2021 financial results with revenue growth and advancements in clinical programs.
Key Takeaways
Ultragenyx reported a total revenue of $87.0 million for the second quarter of 2021, which includes $44.7 million from Crysvita. The company reaffirmed its 2021 guidance for Crysvita revenue in Ultragenyx territories to be between $180 million and $190 million.
Total revenue for Q2 2021 was $87.0 million, including $44.7 million from Crysvita revenue in Ultragenyx territories.
Crysvita revenue in Ultragenyx territories increased by 38% compared to Q2 2020, driven by demand from pediatric and adult patients with XLH and TIO.
Dojolvi continues to show strong launch momentum with approximately 220 patients on reimbursed commercial therapy in the United States.
The company is on track to initiate four pivotal clinical trials over the next six months.
Revenue by Segment
Forward Guidance
Ultragenyx reaffirms the 2021 guidance range for Crysvita in Ultragenyx Territories, which is $180 million to $190 million. This includes the North American profit share region and the other regions where product sales are recognized.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...